Drugs / BI 1774 CL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02172118 | Aug → Dec 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1774 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02172118 ↗ |
| Route | Inhaled | “30 μg administered by inhalation with the Respimat® Inhaler” NCT02172118 ↗ |